Concord Biotech (Pre-IPO): Niche Offering Amid Lean Competition to Drive Stable Growth
The IPO consists of offer for sale of 21M shares by Helix Investment Holdings at a price band of INR705ā741/share. Through this IPO, Concord seeks...
416 Views
Syngene International Ltd (SYNG IN): Well-Positioned to Capitalize On Strong Industry Tailwind
Through capacity and capability addition in biologics manufacturing and expansion of commercial API manufacturing, Syngene has expanded...
479 Views
Diviās Laboratories - Miss in 2QFY23; Growth Factors to Face Softness over Medium Term
DIVI delivered an earnings miss in 2QFY23. Reduced traction in Custom Synthesis (CS), coupled with lower operating leverage resulted in an earnings...
445 Views
Piramal Enterprises (PIEL IN): Demerger to Create a Differentiated and Niche Pharmaceutical Business
Shareholdersā nod for the proposed demerger will create pharmaceutical-focused listed entity, which should pave the way for value unlocking due to...
447 Views
Custom Synthesis/Nutraceuticals drive earnings growth
DIVI delivered in line 2QFY22 earnings led by strong offtake in the Custom Synthesis (CS) segment and ramp up in the Nutraceuticals segment. It has...
163 Views